These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Designing metal-contained enzyme mimics for prodrug activation. Du B; Li D; Wang J; Wang E Adv Drug Deliv Rev; 2017 Sep; 118():78-93. PubMed ID: 28412325 [TBL] [Abstract][Full Text] [Related]
5. Self-immolative nitrogen mustard prodrugs for suicide gene therapy. Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097 [TBL] [Abstract][Full Text] [Related]
6. Self-Immolative Linkers Literally Bridge Disulfide Chemistry and the Realm of Thiol-Free Drugs. Riber CF; Smith AA; Zelikin AN Adv Healthc Mater; 2015 Aug; 4(12):1887-90. PubMed ID: 26109168 [TBL] [Abstract][Full Text] [Related]
7. Targeted enzyme prodrug therapies. Schellmann N; Deckert PM; Bachran D; Fuchs H; Bachran C Mini Rev Med Chem; 2010 Sep; 10(10):887-904. PubMed ID: 20560876 [TBL] [Abstract][Full Text] [Related]
8. Ceria Nanozyme and Phosphate Prodrugs: Drug Synthesis through Enzyme Mimicry. Walther R; Huynh TH; Monge P; Fruergaard AS; Mamakhel A; Zelikin AN ACS Appl Mater Interfaces; 2021 Jun; 13(22):25685-25693. PubMed ID: 34033459 [TBL] [Abstract][Full Text] [Related]
9. Design of self-immolative linkers for tumour-activated prodrug therapy. Tranoy-Opalinski I; Fernandes A; Thomas M; Gesson JP; Papot S Anticancer Agents Med Chem; 2008 Aug; 8(6):618-37. PubMed ID: 18690826 [TBL] [Abstract][Full Text] [Related]
10. Smart nanocarriers for enzyme-activated prodrug therapy. Abo Qoura L; Morozova E; Ramaa СS; Pokrovsky VS J Drug Target; 2024 Nov; 32(9):1029-1051. PubMed ID: 39045650 [TBL] [Abstract][Full Text] [Related]
11. Development of prodrugs for enzyme-mediated, tumor-selective therapy. Yoon KJ; Potter PM; Danks MK Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):107-13. PubMed ID: 15777218 [TBL] [Abstract][Full Text] [Related]
12. Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment. Edupuganti VVSR; Tyndall JDATDA; Gamble AB Recent Pat Anticancer Drug Discov; 2021; 16(4):479-497. PubMed ID: 33966624 [TBL] [Abstract][Full Text] [Related]
13. Designer bacteria as intratumoural enzyme biofactories. Lehouritis P; Hogan G; Tangney M Adv Drug Deliv Rev; 2017 Sep; 118():8-23. PubMed ID: 28916496 [TBL] [Abstract][Full Text] [Related]
16. A self-immolative prodrug nanosystem capable of releasing a drug and a NIR reporter for in vivo imaging and therapy. Wang Z; Wu H; Liu P; Zeng F; Wu S Biomaterials; 2017 Sep; 139():139-150. PubMed ID: 28614754 [TBL] [Abstract][Full Text] [Related]
17. What should be considered on design of a colon-specific prodrug? Jung Y; Kim YM Expert Opin Drug Deliv; 2010 Feb; 7(2):245-58. PubMed ID: 20095945 [TBL] [Abstract][Full Text] [Related]
18. Identification of human, rat and mouse hydrolyzing enzymes bioconverting amino acid ester prodrug of ketoprofen. Huttunen KM Bioorg Chem; 2018 Dec; 81():494-503. PubMed ID: 30243240 [TBL] [Abstract][Full Text] [Related]
19. Selective activation of anthracycline prodrugs for use in conjunction with ADEPT. HariKrishna D; Rao AR; Krishna DR Drug News Perspect; 2003 Jun; 16(5):309-18. PubMed ID: 12942162 [TBL] [Abstract][Full Text] [Related]
20. Targeted prodrug design to optimize drug delivery. Han HK; Amidon GL AAPS PharmSci; 2000; 2(1):E6. PubMed ID: 11741222 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]